Microsoft: Azure Skies, Premium Altitude
Maia Biotechnology Inc MAIA
$1.25
▲ +0.00%
(+$0.00)
🗓️ Earnings Next Week
Open
$1.25
Prev Close
$1.25
Day Range
$1.21 – $1.27
52W Range
$0.87 – $3.19
Market Cap
$76.00M
Beta
0.25
EPS (TTM)
$-0.68
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NYSE MKT LLC |
| Currency | USD |
| IPO Date | 2022-07-28 |
| Shares Out. | 60,800,000 |
| Website | maiabiotech.com/ ↗ |
| Phone | 18004831140 |
| Employees | 13 |
| Net Income | -$6.4M |
| Total Assets | $35.3M |
| Total Liabilities | $7.6M |
| Equity | $27.8M |
About Maia Biotechnology Inc
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.
Maia Biotechnology Inc is a publicly traded company under the ticker symbol MAIA on the NYSE MKT LLC, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-07-01)